The Indian industry has grown manifold since independence and today is ranked among the major global players. This has been a result of several factors which together have provided the right environment for India’s growth. However, given the fast pace of change, appropriate course corrections and suitable policy interventions are necessary for sustenance of future growth. In this paper, the authors present an argument rooted on innovativeness of Indian pharmaceutical industry to demonstrate how future growth possibilities can be created and sustained. Some of the challenges besieging the process have been identified as lack of skilled manpower, inadequate finances, low technological base and limited access to new technologies. The final results provide foundations of a business model having the potential of nurturing an innovative ecosystem in India in order to transform India into a producer of innovative pharmaceutical products.
Greene W. The emergence of India's pharmaceutical industry and implications for the US generic drug market. US International Trade Commission, Office of Economics, Washington, DC, USA, 2007.
4.
Government of India. Annual report. Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, New Delhi, India, 2011–12.
5.
ChesbroughHRosenbloomRS. The role of the business model in capturing value from innovation: evidence from Xerox Corporation's technology spin-off companies. Industrial Corporate Change2002; 11: 529–55.
6.
TeeceDJ. Business models, business strategy and innovation. Long Range Plann2010; 43: 172–94.
YadavP. Differential pricing for pharmaceuticals: review of current knowledge, new findings and ideas for action, Great Britain: Department for International Development, 2010.
24.
LichtenbergFRPetterssonB. The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data. Economics Innovation New Technology2014; 23: 239–273.
